
The study investigated the impact of abatacept (ABT) on atherosclerosis in rheumatoid arthritis (RA) patients over three years, comparing older and younger individuals. While not statistically significant, the ABT group showed smaller increases in certain atherosclerosis markers than the csDMARD group. Multivariate analysis indicated lower plaque score increases with ABT, particularly in patients with active disease. ABT also improved rheumatoid arthritis symptoms, with no significant age-related differences. However, serious adverse effects, notably infections, were more frequent with ABT. Overall, ABT may slow atherosclerosis progression, benefiting high-risk patients like older individuals.
Like
Save
Share